Cosmos Health (COSM) Launches Subscription Model

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands.

The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase rate above 60% and margins in excess of 50%. NOOR Collagen is a proprietary product formulated with premium marine collagen tripeptide, currently available in capsule form, with a formula designed to support skin and joint health.

The Company plans to extend the subscription model to a broader range of its consumer health products across its brands and markets globally, with further initiatives already underway. Cosmos Health expects the model to offer several benefits:

• Recurring revenue: Converts one-time purchases into ongoing subscriptions, generating predictable, recurring revenue.
• Cash-flow visibility: Improves forward visibility into revenue and demand over time.
• Product bundling: Lets consumers combine multiple products in a single subscription, increasing convenience and average order value.
• Personalized guidance: Gives subscribers access to nutritionists and wellness consultants to tailor product selections to their goals.
• Stronger customer relationships: Deepens loyalty and lifetime value through an ongoing, direct relationship with consumers.
  

The Company expects to provide additional details, including sales, repeat purchase and retention rates, and margins, as the model matures.

Greg Siokas, CEO of Cosmos Health, stated: "A subscription model is a natural next step in deepening our relationship with consumers and building recurring revenue across our brands. The early response to our NOOR Collagen subscription in the United States has been encouraging, and by pairing our science-driven products with personalized guidance, we believe we can drive stronger loyalty, greater lifetime value, and more predictable revenue as we grow.”

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP
• Tesco explores sale of Central and Eastern Europe operations, Morgan Stanley chimes in